Molnupiravir, an antiviral developed by Merck & Co. works by causing mutations in the virus with the aim of weakening and then killing it, thus reducing the amount of virus in the body.

A new study said Merck's widely used antiviral Covid pill can cause mutations in the virus that occasionally spread to other ...

Merck already has a supply deal in place for molnupiravir with the US government, which has agreed a $1.2 billion order for 1.7 million doses at a price of $700 per course, as well as deals with ...

The US has also ordered 3.1 million doses of molnupiravir for around $2.2 billion. Merck – which is developing the drug with Ridgeback Biotherapeutics – is one step ahead for a regulatory ...

Ridgeback and Merck have partnered to develop molnupiravir and will share profits. In some of the children Denison treats as the director of pediatric infectious diseases at VUMC, remdesivir ...

There’s a new drug in the wings to treat Covid, an at-home treatment called molnupiravir. Merck Pharmaceutical’s new “Covid pill” will supposedly be accessible medicine to treat ...

While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...

An experimental COVID-19 treatment pill called Molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and ...

Merck and Ridgeback Biotherapeutics announced on Friday early result that indicate their experimental oral antiviral drug molnupiravir might halve the risk of death or hospitalization from COVID-19.

The Food and Drug Administration announcement on Merck's molnupiravir comes one day after the agency cleared a competing drug from Pfizer. Pfizer's pill, Paxlovid, is likely to become the first ...

Molnupiravir, developed by the US drug companies Merck, Sharp and Dohme (MSD) and Ridgeback Biotherapeutics, is the first antiviral medication for Covid which can be taken as a pill rather than ...

Merck now finds itself in a position to make molnupiravir one of its most profitable drugs, with industry analysts forecasting the company will make about $22 billion in revenue from the drug ...